About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

ICS/LABA Adherence and COPD Exacerbation | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT02446041

ICS/LABA Adherence and COPD Exacerbation

The purpose of this retrospective, non-interventional sutdy is to compare the effectiveness of ICS/LABA combination therapy in the reduction of COPD exacerbations during the 12 months after initiation...

Lead sponsor: AstraZeneca•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

AstraZeneca

Collaborators

Carelon Research

This retrospective, observational study will assess the effectiveness of ICS/LABA combination therapies among COPD patients new to the ICS/LABA combination therapies in the US, comparing those who are adherent to the index medication and those who are non-adherent. Adherence will be measured using the proportion of days covered with the index medication. Medical and pharmacy claims data will be used as the data source.

Age

40 - 99 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•at least one prescription fill for ICS/LABA combination during identification period.
•COPD diagnosis
•40 years or older at index date
•\> or = 12 months of continuous health plan enrollment prior to and following index date
•1 or more prescription for SABA, SAMA or SABA/SAMA during the pre-index period.

Exclusion Criteria

•Patients with prescription claim for ICS/LABA combination therapy during the 12 month pre-index period
•Patients receiving oral corticosteroid medication for more than 180 days during the 12 month pre-index period
•Patients with cancer diagnosis in 12 month pre-index period

Related studies

Health Impact of Non-Tuberculous Mycobacteria Pulmonary Disease (NTM-PD)

NCT07192705 · Non-Tuberculous Mycobacteria Pulmonary Disease, Bronchiectasis

CLEAR Model for Predicting Ventilatory Liberation in Severe COPD

NCT07579052 · Chronic Obstructive Pulmonary Disease

Pulmonary Rehabilitation for Rural Patients With COPD

NCT06847061 · Chronic Obstructive Pulmonary Disease (COPD

RECRUITINGPhase 2

Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD

NCT05061368 · Chronic Obstructive Pulmonary Disease

RECRUITINGPhase 3

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

NCT07190209 · Chronic Obstructive Pulmonary Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 11, 2016Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment10,000

Start dateMay 2015

Last updatedOct 11, 2016

Condition

Pulmonary Disease Chronic Obstructive

Locations shown

Research Facility

Wilmington, Delaware

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 11, 2016Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions